Clinically relevant candidate genes for pain management
Cellular transporters control the uptake, distribution and elimination of drugs. P-glycoprotein is an efflux transporter also called adenosine triphosphate-binding cassette, subfamily B, member 1 (ABCB1) or multidrug resistance 1 (MDRD1) [5] . It is expressed in hepatic, intestinal and renal epithelial cells and also on the luminal side of endothelial cells in the blood-brain barrier, and it is a major determinant of the pharmacokinetics and pharmacodynamics of several opioids (such as morphine, methadone and fentanyl) commonly used to treat pain [5] . Genetic variants (such as 3435C>T) in P-glycoprotein have been associated with variability of pain relief in cancer patients treated with morphine [6] . e analgesic effects of morphine are mediated by its interaction at the µ-opioid receptor located in the central nervous system (CNS). P-glycoprotein can limit the concentration of pain management drugs, such as morphine, in the brain because it actively pumps drugs out of the CNS. As a result, homozygous carriers of the 3435C>T variant (TT carriers) experience greater pain relief than heterozygous (CT) or homozygous wild-type (CC) carriers, presumably because higher concentrations
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of morphine can be achieved in the CNS [6] . Table 1 lists the clinically relevant pharmacogenomic targets for pain management.
The cytochrome P450 (CYP) system is responsible for metabolizing a wide range of therapeutic agents used for pain relief. CYP2D6 is especially important for the activation or inactivation of several opioids used to treat pain, including codeine, oxycodone and tramadol [7] . Typically, the genetic variability of CYP can be grouped into four phenotypes: ultrarapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM) and poor metabolizers (PM). UMclassified patients typically contain multiple copies of a gene, which results in an increase in drug metabolism [8] . EMclassified patients are characteristic of the normal population and have a single wildtype copy of the gene, whereas IM classified patients show decreased enzymatic activity and PMclassified patients have no detectable enzymatic activity [8] . Codeine is a prodrug that requires demethy lation to its active metabolite morphine by CYP2D6 before it can exert an analgesic effect. As a result, CYP2D6 PMclassified patients experience ineffective analgesia and increased side effects from the parent drug (codeine) [7] . On the other hand, CYP2D6 UMclassified patients prescribed codeine for pain management generate extensive concentrations of morphine, which can lead to ADRs [9] .
Tramadol, another opioid commonly used for pain management, produces analgesia by the synergistic action of its two enantiomers and their metabolites [7] . Tramadol undergoes metabolism by CYP2D6 to an active metabolite (Odesmethyl tramadol), which has greater affinity for the µopioid receptor than does the parent compound [7] . Genetic variations in CYP2D6 have been shown to account for some of the variable pain response in the postoperative period because the CYP2D6 activity has a clinically relevant impact on the level of analgesia mediated by the µopioid receptor [10] .
Another important genetic target is uridine diphosphateglucuronosyltransferase 2B7 (UGT2B7), which metabolizes morphine to morphine 3glucuronide (M3G) and morphine 6glucuronide (M6G). The latter has a higher analgesic potency than the parent compound [11] . Morphine is commonly used to control moderate and severe pain associated with sickle cell disease. Darbari et al. [12] showed that the presence of the UGT2B7 840G>A genotypes (GG and GA) were associated with lower M3G:morphine and M6G:morphine ratios than AA genotypes. As a result, genetic poly morphisms in UGT2B7 have been shown to decrease the hepatic clearance of morphine, which translates into lower dosage requirements of morphine [12] . In another study [13] , the UGT2B7*2 polymorphism (802C>T) was also shown to be associated with the frequency of morphineinduced ADRs (nausea) in cancer patients. The authors showed that the frequency of nausea was higher in patients without the UGT2B7*2 allele [13] .
Furthermore, the efficacy of opioid analgesia can be enhanced by the coadministration of catecholamines, which are involved in the modulation of pain [14] . CatecholOmethyltransferase (COMT) is responsible for the inactivation of catecholamines (dopamine, adrena line and norepinephrine). As a result, genetic variability in the COMT gene can contribute to differ ences in pain sensitivity and response to analgesics. It has been shown that a common variant allele (1947G>A; Rs4680) results in a three to fourfold reduction in COMT enzyme activity [15] . Homozygous wildtype (GG) cancer patients required higher doses of morphine to control pain than heterozygous or homozygous variant (AA) alleles [16, 17] .
Finally, the µopioid receptor encoded by the opioid receptorlike 1 (OPRM1) gene is the primary site of action for most of the commonly used opioids. The 118A>G polymorphism in this gene results in less effective opioid analgesia, as reported with cancer patients with homozygous variant alleles (GG) who required higher morphine doses for pain relief than homozygous wildtype (AA) participants [18] . In another study [19] , Chou et al. investigated the correlation between the 118A>G polymorphism and patient controlled morphine consumption in patients undergoing total knee arthroplasty. Patients who were homozygous variants (GG) consumed approximately 60% more morphine than patients who were heterozygous or homozygous wildtype (AA) during the first 48hour postoperative period. Patient demographics, reported pain and other factors did not differ between the genotype groups. In a similar study [20] , women who had homozygous variants for the 118A>G polymorphism required 30% more morphine to achieve adequate pain control than those who were wild type (AA) during the first 24 hours after a total abdominal hysterectomy. Finally, a significant relationship between the degree of pain relief and the 118A>G genotypes was shown in cancer patients being treated with morphine over the first 2 months of therapy [6] . In the first 7 days of morphine treatment, patients homozygous for the wild type allele (AA) had more pronounced decrease in pain from baseline than those who were homozygous variants (GG), whose response was almost undetectable [6] .
Limitations and future directions of pharmacogenomics for pain management
Genomic variations clearly influence pain sensitivity, the likelihood of developing chronic pain and the response to pharmacotherapy for the management of pain [21, 22] . Pharmacogenomic polymorphisms are definitely impor tant in the interindividual variability in the analgesic effects and occurrence of ADRs of commonly used medications prescribed for pain management, but genetic factors will provide only a partial answer to the interindividual variability observed. Other factors, includ ing biological variations (ethnicity, age and gender), environmental factors (smoking status), co morbidity and comedications (potential for drugdrug interactions) must be considered along with the genetic variations because together they all affect the pharmaco kinetics and pharmacodynamics of medications used for pain management. Additional studies are also needed to characterize the combined effects of multiple genes along with demographic and clinical variables in selecting the appropriate opioid and predicting the appropriate opioid dose in patients with pain. Large, randomized prospective studies are needed to develop appropriate dosing or treatment algorithms to facilitate the use of genotyping information appropriately by physicians. Furthermore, the continued development of regulatorapproved geno typing assays to identify these variant alleles will allow greater access to this information to aid in daytoday clinical decisions for acute and chronic pain manage ment. The benefits of patient care and safety will result in the incorporation of this knowledge into the standard of care for anesthesiologists and pain management physi cians. In the near future, pharmacogenomic approaches in pain management could lead to individualized therapy to best select the appropriate analgesic from the onset to provide sustained efficacy with the lowest side effect profile.
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